ONKURE THERAPEUTICS INC/$OKUR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
- Ticker
- $OKUR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 45
- Headquarters
- Boulder, United States
- Website
- onkuretherapeutics.com
OKUR Metrics
BasicAdvanced
$136M
-
-$1.94
0.73
-
Price and volume
Market cap
$136M
Beta
0.73
52-week high
$5.38
52-week low
$2.01
Average daily volume
443K
Financial strength
Current ratio
18.841
Quick ratio
18.581
Long term debt to equity
0.003
Total debt to equity
0.005
Interest coverage (TTM)
-10,998.33%
Profitability
EBITDA (TTM)
-65.642
Management effectiveness
Return on assets (TTM)
-34.38%
Return on equity (TTM)
-55.18%
Valuation
Price to book
0.86
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
-2.234
Free cash flow yield (TTM)
-44.77%
Free cash flow per share (TTM)
-1.504
Growth
Earnings per share change (TTM)
-59.24%
OKUR Financial Performance
Revenues and expenses
OKUR Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.